ClinicalTrials.gg
RecruitingNCT01193075INC-6601Updated Oct 26, 2026

Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

An observational study in Charcot Marie Tooth Disease, sponsored by Michael Shy. Recruiting at 24 sites in 6 countries. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Michael Shy · Observational

How we know

From the registry’s dates

  • Started Apr 2010; still recruiting 16 years 7 months later.
Updated Oct 16, 2026First site in CyprusSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies in Charcot-Marie-Tooth Disease with a site in United States — 9 open to participants now, 14 under way, 2 of them phase 3. Charcot-Marie-Tooth Disease · United States.

Planned enrollment
4th of 21
5,000 · median 291
Started
2010
with 2 others
Observational
21 of 41
8 open now
Primary completion
2030-12
later than 7 of 13 live
Registered
3rd of 41
by date

Among the 41 studies in Charcot-Marie-Tooth Disease with a site in United States, this one is the 4th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2010, is one of 21 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 3rd registered.

Charcot-Marie-Tooth Disease

115 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 39 are open to participants now.

Browse Charcot-Marie-Tooth Disease studies →

Open to participants now

9 of the 41 studies in Charcot-Marie-Tooth Disease with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Charcot-Marie-Tooth Disease studies recruiting now, 14 (45%) set no upper age limit and 13 (42%) stop at 75 or younger; 14 take children under 18; 13 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Charcot-Marie-Tooth Disease with a site in United States, or all of them as a file.
02

Study summary

This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).

The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window

Read the detailed description

The Inherited Neuropathies Consortium (INC) is a member of the Rare Disease Clinical Research Network (RDCRN) that is funded by the National Institutes of Health (NIH) through the Office of Rare Diseases (ORD) and the NINDS. The University of Iowa is the lead center in INC which also includes sites from the University of Pennsylvania, Children's Hospital of Philadelphia (CHOP), the University of Rochester (NY), the National Hospital for Neurology and Neurosurgery in London England, the Dubowicz Neuromuscular Center, and the University of Miami (Florida). The North American CMT Network is an additional consortium that is funded by the Muscular Dystrophy Association (MDA) and the Charcot Marie Tooth Association (CMTA). The University of Iowa is the lead site for this consortium as well. Additional sites include the University of Washington (Seattle), Vanderbilt University, Johns Hopkins University, the University of Sydney, the Besta Neurological Institute in Milan (Italy), Harvard University and the intramural Neurogenetics division of the NIH. All funding sources have agreed to allow us to house data from the two consortia together at the NIH funded Data Management Coordinating Center (DMCC) at the University of South Florida and to group them under the name of the Inherited Neuropathies Consortium (INC).

The inherited peripheral neuropathies are often called Charcot Marie Tooth Disease (CMT), named after the three physician scientists who first described them. These are a heterogenous group of disorders caused by mutations in more than 50 different genes. The diseases cause weakness and loss of sensation in patients. There are no effective treatments for any forms of CMT. There is also limited information on the natural history of how any of the different types of CMT progress and limited outcome measures to measure impairment. The purpose of INC is to investigate the natural history of the different types of CMT, to identify genes that modify the severity of individual types of CMT, to develop and test outcome measures for children with CMT, to develop an interactive website for patients with CMT and to develop the knowledge needed to perform clinical trials in patients with CMT.

To do this, people who have, are suspected to have, or have a family history of an inherited neuropathy will take part in a full-day evaluation. These patients are being seen in order to receive a possible diagnosis of CMT and clinical care, but may also choose to participate in this research project. Most of the testing being performed would be done as part of the standard of care for diagnosing and treating a patient with an inherited neuropathy. Additional testing may be performed on certain subjects if applicable, but the majority of subjects who volunteer for this study are allowing us to use the clinical information obtained during their visit as coded data for natural history purposes and to develop outcome measures.

Because all individuals who attend the CMT clinic would be eligible for participation in this study, when they arrive for their clinic visit, the initial meeting is to review the consent form for the research project. Thus, the evaluation will begin with consenting subjects into the study, if applicable. Then, a variety of tests will take place to measure the presence and severity of symptoms, along with identifying which type of CMT a patient/subject may have. Tests included in this study which are also the standard of care for patients with inherited neuropathies include a neurological evaluation by a trained neurologist, a limited set of nerve conduction studies, physical therapy assessment, orthotist assessment, genetic counseling, and possibly genetic testing to determine the form of CMT. Additional clinical testing which may be used for research includes EMGs or MUNE testing to evaluate possible muscular dystrophies or muscle involvement in the disease. The results from these tests will be used for diagnostic purposes and to give each patient a CMT Neuropathy Score (CMTNS) which is a validated instrument that allows us to assess the severity of disease based on a 36 point scale. If the subject is also involved in the research project, the results will also be used for research purposes.

Additionally, some subjects may undergo testing which is not a part of regular clinical care, but is being done for research purposes only. These tests/procedures may include hand function testing, physical assessment using the CMT Peds Score (an instrument used to evaluate children with CMT - see substudy 6603), research based genetic testing, quality of life questionnaires, or a skin biopsy. All of these tests/procedures are optional, subjects do not have to complete these to be involved in the overall natural history study. Opting out of any of these procedures does not mean that they would be excluded from the study. Some of these procedures would only be performed on certain individuals who are eligible based on age or type of CMT. Skin biopsies are being performed on certain qualified subjects for research purposes in order to grow fibroblast cells to further study various forms of CMT. These individuals would be over 18 and have specific forms of CMT.

Additionally, there are sub-studies that are being performed which SOME subjects may be eligible for. These sub-study options will be discussed with each patient prior to their participation.

Sub-study #6601 - Test-retest protocol addendum for pCMT-QOL. Substudy for a small group of subjects in order to assess the test-retest reliability indicates reproducibility of the pCMT-QOL. In order to calculate test-retest reliability, at a single site of the Inherited Neuropathy Consortium (University of Iowa), 25 subjects aged 8-18 and their parents will be given the appropriate version of pCMT-QOL, as well as the parents of 10 subjects aged 7 and under. These parents will in addition be given a pre-stamped envelope containing the same version of the pCMT-QOL that they took, to be completed by their child and/or parent in 4 weeks and return by mail (in CMT, the disease should not fluctuate in a 4 week interval). Parents will be given one reminder phone call in 6-8 weeks, and the pCMT-QOL forms will be mailed to them again if they are reported missing. Test-retest reliability will be estimated by intraclass correlation coefficients (two-way random effects model) to show correlations between any given individual's scores in two QOL assessments taken 4 weeks apart.

Sub-study #6602 - This project is to understand modifier genes and how they influence the severity of disease expression, along with identifying new forms of CMT which have not been genetically determined. Subjects who are eligible will either have CMT type 1A (CMT1A) or an unknown form of CMT type 2 (CMT2). Blood will be drawn and sent to the University of Miami where they receive the coded sample and process it through exome sequencing. Subjects will be told that this is optional.

These tests will be performed in one day during the clinic visit. Patients who attend the clinic are given the option of returning for annual visits to help with disease management. If a patient decides to follow up in the clinic, they will once again be asked to participate in the research. They do not need to participate in the research in order to be seen in the clinic, and they can opt out at any time. If a subject does not follow up by making an appointment in the clinic, they will not be contacted by us to schedule a return visit. All return visits are initiated by the patient/subject. An individual can decide not to participate in the research, but will still be able to be seen in the clinic and receive medical recommendations, treatment, and care by the clinical team who specializes in inherited neuropathies.

03

Conditions studied

  • Charcot Marie Tooth Disease

Keywords

  • Charcot Marie Tooth disease
  • CMT
  • HMSN
  • HMN
  • HSN
  • CMT1
  • CMT2
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients who present to a participating site and have Charcot Marie Tooth disease (CMT) will be recruited for participation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Criteria

1. All patients must agree to take part in the study and sign a consent form. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).

Patients:

  1. Must have a documented, disease-causing variant(s) in a gene with a known or preliminary association with CMT gene as per Strande et al. 2017 AND consistent with the inheritance pattern associated with the genetic subtype (heterozygous in autosomal dominant, biallelic in autosomal recessive, hemizygous males with X-linked).
  2. OR have a first- or second-degree family member (parent, child, sibling, half-sibling, aunt, uncle, grandparent, or grandchild) with a documented disease-causing variant(s) as above AND a clear link between that family member and the affected patient AND a phenotype consistent with the diagnosis.
  3. In cases where clear links are not available, genetic confirmation is required.
  4. Patients who have a variant(s) of uncertain significance on clinical laboratory reports may still be included if:
  5. The variant is categorized as pathogenic or likely pathogenic per the "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology." (Richards et al., 2015)
  6. OR the variant has been found in multiple affected people in a family and has not been found in unaffected family members per "ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classification." (Biesecker et al. 2023)
  7. OR the principal investigator and the site investigator agree that the variant(s) is (are) likely disease-causing.

Controls

  1. Must not have a peripheral neuropathy, as determined by the site investigator.
  2. Must have understood and signed an IRB approved consent form for the study. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).

Exclusion criteria

Exclusion Criteria

Patients:

  1. Patient does not wish to participate or does not sign a consent form.
  2. Patient has a different potential cause for their neuropathy AND no disease-causing variant(s).
  3. Deemed inappropriate by the Site PI.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)

Groups and cohorts

  • CMT1B

    Families/patients with genetically confirmed CMT1B

  • CMT2A

    Families/patients with genetically confirmed CMT2A

  • CMT4A

    Families/patients with genetically confirmed CMT4A

  • CMT4C

    Families/patients with genetically confirmed CMT4C

  • All other CMT

    Families/patients with all other forms of CMT or CMT that has not yet been genetically identified

06

What researchers measure

Primary outcomes

  1. Charcot Marie Tooth Neuropathy Score (CMTNS)

    Charcot Marie Tooth Neuropathy Score (CMTNS) is a composite measure of disability based on a person's symptoms, signs, and electrophysiology. It is based on a 36 point scale, with 9 items each worth up to 4 points. A higher score signifies increased disability.

    Time frame: 1 year

  2. Minimal dataset

    This includes diagnosis, family history, developmental history, walking ability, hand function, strength, sensation, and neurophysiology.

    Time frame: 1 year

07

Study locations

24 of 24 sites recruiting
08

References and documents

Publications

  • Fridman V, Sillau S, Acsadi G, Bacon C, Dooley K, Burns J, Day J, Feely S, Finkel RS, Grider T, Gutmann L, Herrmann DN, Kirk CA, Knause SA, Laura M, Lewis RA, Li J, Lloyd TE, Moroni I, Muntoni F, Pagliano E, Pisciotta C, Piscosquito G, Ramchandren S, Saporta M, Sadjadi R, Shy RR, Siskind CE, Sumner CJ, Walk D, Wilcox J, Yum SW, Zuchner S, Scherer SS, Pareyson D, Reilly MM, Shy ME; Inherited Neuropathies Consortium-Rare Diseases Clinical Research Network (INC-RDCRN). A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores. Neurology. 2020 Mar 3;94(9):e884-e896. doi: 10.1212/WNL.0000000000009035. Epub 2020 Feb 11. PubMed 32047073 ↗
  • Panosyan FB, Laura M, Rossor AM, Pisciotta C, Piscosquito G, Burns J, Li J, Yum SW, Lewis RA, Day J, Horvath R, Herrmann DN, Shy ME, Pareyson D, Reilly MM, Scherer SS; Inherited Neuropathies Consortium-Rare Diseases Clinical Research Network (INC-RDCRN). Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease (CMTX1). Neurology. 2017 Aug 29;89(9):927-935. doi: 10.1212/WNL.0000000000004296. Epub 2017 Aug 2. PubMed 28768847 ↗
  • Fridman V, Bundy B, Reilly MM, Pareyson D, Bacon C, Burns J, Day J, Feely S, Finkel RS, Grider T, Kirk CA, Herrmann DN, Laura M, Li J, Lloyd T, Sumner CJ, Muntoni F, Piscosquito G, Ramchandren S, Shy R, Siskind CE, Yum SW, Moroni I, Pagliano E, Zuchner S, Scherer SS, Shy ME; Inherited Neuropathies Consortium. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry. 2015 Aug;86(8):873-8. doi: 10.1136/jnnp-2014-308826. Epub 2014 Nov 27. PubMed 25430934 ↗

Individual participant data

Plan to share: Yes — De-identified RDCRN data is submitted to an ORDR-designated repository. For the current grant cycle, that repository has been dbGaP.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: For Observational/Longitudinal/Natural History/Epidemiology studies): For the current grant cycle, available data will be released to the repository and will become available to the scientific community one year after publication of planned analyses, or after a period of 5 years from the date when the data were collected, whichever comes first.

Access criteria: - For the current grant cycle, once de-identified data is posted on dbGaP, a summary of the study is posted and individual participant data is accessed via a request through dbGaP.

Data sharing details ↗ · www.ncbi.nlm.nih.gov

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2010 (actual). Primary completion is estimated for Dec 2030, 248 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2026 → Dec 2030 and completion Dec 2026 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2010
First posted
Sep 1, 2010
StartActual
Apr 1, 2010
Primary completionEst.
Dec 2030was Dec 2026
CompletionEst.
Dec 2030was Dec 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 3 sites removed — first site in Cyprus. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • University of Michigan · Ann Arbor, United StatesNot yet recruiting→Recruiting
  • Seattle Children's Hospital · Seattle, United StatesNot yet recruiting→Recruiting
Show 5 added (3 United States, 1 Cyprus, 1 United Kingdom)
  • University of North Carolina · Chapel Hill, United States
  • Nationwide Children's Hospital · Columbus, United States
  • Houston Methodist Hospital · Houston, United States
  • The Cyprus Institute of Neurology & Genetics · Nicosia, Cyprus
  • Great Ormond Street Hospital · London, United Kingdom
Show 3 removed
  • Children's National Hospital · Washington D.C., United States
  • Nemours Children's Health · Orlando, United States
  • Nemours Children's Hospital · Orlando, United States
Oct 16, 2026
Primary completion
Dec 2026→Dec 2030
Oct 16, 2026
Study completion
Dec 2026→Dec 2030
Oct 16, 2026
Eligibility
8 inclusion criteria edited, 5 added; 2 exclusion criteria edited, 2 added; 13 criteria removed
What changed in the criteria
  • RemovedAll patients must be seen in-person at a participating center for the initial visit.
  • RemovedInclusion Criteria - patients with CMT (all subtypes)
  • RemovedPatient has documented, pathogenic or likely pathogenic CMT-causing variant(s)
  • RemovedOR
  • RemovedInclusion Criteria - Controls
  • RemovedA clear link is necessary for a second-degree relative. For example, if a grandparent is affected and has a pathogenic or likely pathogenic variant, and the parent does not have any signs, symptoms, or electrophysiology consistent with the diagnosis, there is no clear link unless the parent has also been found to have the pathogenic or likely pathogenic variant such as in cases with reduced penetrance
  • RemovedVariant is categorized as pathogenic or likely pathogenic per the ACMG variant interpretation guidelines. [80, 81]
  • RemovedVariant has been found in multiple affected people in a family and has not been found in unaffected family members. (Note - both affected and unaffected family members must be tested in this situation to be included).
  • RemovedPatients whose clinical presentation is suggestive of CMT, but CMT type and variant are unknown will be characterized by the following categories:
  • RemovedNerve conduction velocities: demyelinating, axonal, intermediate
  • RemovedInheritance: dominant, recessive, X-linked, or unknown
  • RemovedEXCLUSION CRITERIA
  • RemovedPatient has a variant of uncertain significance that cannot be further classified following methods listed in the Inclusion Criteria.
Inclusion criteria
  • EditedInclusionGeneral Criteria:
  • EditedPatient or patient's legally authorized representative has understood1. All patients must agree to take part in the study and signed an IRB approvedsign a consent form for the study. Teenagers (age 13 - 17 years) and cognitively impaired adults who are able to read and write must sign an assent form (depending on local ethics committee requirements).
  • AddedPatients:
  • AddedMust have a documented, disease-causing variant(s) in a gene with a known or preliminary association with CMT gene as per Strande et al. 2017 AND consistent with the inheritance pattern associated with the genetic subtype (heterozygous in autosomal dominant, biallelic in autosomal recessive, hemizygous males with X-linked).
  • EditedPatient hasOR have a first- or second-degree family member (parent, child, sibling, half-sibling, aunt, uncle, grandparent, or grandchild) with a documented pathogenic or likely pathogenic CMTdisease-causing variant(s) as above AND a clear link between that family member and the affected patient AND a phenotype consistent with the diagnosis.
  • EditedIn cases where clear links are not available, genetic testingconfirmation is required for the patient or the family member who is not clearly affected.
  • EditedPatients who have a variant(s) of uncertain significance, as determined by the on clinical laboratory performing the testingreports may still be included if one of the following circumstances applies:
  • AddedThe variant is categorized as pathogenic or likely pathogenic per the "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology." (Richards et al., 2015)
  • AddedOR the variant has been found in multiple affected people in a family and has not been found in unaffected family members per "ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classification." (Biesecker et al. 2023)
  • EditedTheOR the principal investigator and the site investigator agree that the variant(s) is (are) most likely pathogenicdisease-causing.
  • AddedControls
  • EditedPerson doesMust not have a peripheral neuropathy, as determined by the site investigator.
  • EditedPerson hasMust have understood and signed an IRB approved consent form for the study. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).
Exclusion criteria
  • AddedPatients:
  • EditedPatient does not wish to be a part of the studyparticipate or hasdoes not signed an informedsign a consent form.
  • AddedPatient has a different potential cause for their neuropathy AND no disease-causing variant(s).
  • EditedPatient is deemedDeemed inappropriate by the Site PI.
Oct 16, 2026
Site contacts
Changed at 11 sites. See the sites
Show 11 sites
  • Cedars-Sinai Medical Center · Los Angeles, United StatesContact t•••@cshs.org · •••4268→Y•••@cshs.org
  • Stanford University · Palo Alto, United StatesContact c•••@standfordmed.org · •••5588→m•••@stanford.edu
  • University of Colorado Hospital · Aurora, United StatesContact b•••@ucdenver.edu · •••6386→N•••@cuanschutz.edu
  • University of Miami · Miami, United StatesContact l•••@med.miami.edu · •••2550→l•••@med.miami.edu
  • Harvard/Massachusetts General Hospital · Boston, United StatesContact n•••@mgh.harvard.edu · •••6996→l•••@mgh.harvard.edu
  • University of Michigan · Ann Arbor, United StatesContact q•••@med.umich.edu→k•••@med.umich.edu
  • University of Minnesota · Minneapolis, United StatesContact h•••@umn.edu→f•••@umn.edu
  • University of Pennsylvania · Philadelphia, United StatesContact p•••@pennmedicine.upenn.edu→d•••@pennmedicine.upenn.edu
  • University of Westmead · Sydney, AustraliaContact person changed (no phone or email listed)
  • C. Besta Neurological Institute · Milan, ItalyContact d•••@istituto-besta.it · •••3001→e•••@istituto-besta.it
  • National Hospital of Neurology and Neurosurgery · London, United KingdomContact •••8024→none listed
across 2 updates, Oct 16, 2026 – Oct 26, 2026
Sponsor
Collaborators removed: Nemours Children's Hospital
Oct 16, 2026
Show all 2 updates
  1. Oct 26, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Hospital of Neurology and Neurosurgery · London, United KingdomContact •••8024→none listed
  2. Oct 16, 2026
    5 sites added, 3 sites removed — first site in Cyprus. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • University of Michigan · Ann Arbor, United StatesNot yet recruiting→Recruiting
    • Seattle Children's Hospital · Seattle, United StatesNot yet recruiting→Recruiting
    Show 5 added (3 United States, 1 Cyprus, 1 United Kingdom)
    • University of North Carolina · Chapel Hill, United States
    • Nationwide Children's Hospital · Columbus, United States
    • Houston Methodist Hospital · Houston, United States
    • The Cyprus Institute of Neurology & Genetics · Nicosia, Cyprus
    • Great Ormond Street Hospital · London, United Kingdom
    Show 3 removed
    • Children's National Hospital · Washington D.C., United States
    • Nemours Children's Health · Orlando, United States
    • Nemours Children's Hospital · Orlando, United States
    Primary completion Dec 2026→Dec 2030
    Study completion Dec 2026→Dec 2030
    Eligibility 8 inclusion criteria edited, 5 added; 2 exclusion criteria edited, 2 added; 13 criteria removed
    What changed in the criteria
    • RemovedAll patients must be seen in-person at a participating center for the initial visit.
    • RemovedInclusion Criteria - patients with CMT (all subtypes)
    • RemovedPatient has documented, pathogenic or likely pathogenic CMT-causing variant(s)
    • RemovedOR
    • RemovedInclusion Criteria - Controls
    • RemovedA clear link is necessary for a second-degree relative. For example, if a grandparent is affected and has a pathogenic or likely pathogenic variant, and the parent does not have any signs, symptoms, or electrophysiology consistent with the diagnosis, there is no clear link unless the parent has also been found to have the pathogenic or likely pathogenic variant such as in cases with reduced penetrance
    • RemovedVariant is categorized as pathogenic or likely pathogenic per the ACMG variant interpretation guidelines. [80, 81]
    • RemovedVariant has been found in multiple affected people in a family and has not been found in unaffected family members. (Note - both affected and unaffected family members must be tested in this situation to be included).
    • RemovedPatients whose clinical presentation is suggestive of CMT, but CMT type and variant are unknown will be characterized by the following categories:
    • RemovedNerve conduction velocities: demyelinating, axonal, intermediate
    • RemovedInheritance: dominant, recessive, X-linked, or unknown
    • RemovedEXCLUSION CRITERIA
    • RemovedPatient has a variant of uncertain significance that cannot be further classified following methods listed in the Inclusion Criteria.
    Inclusion criteria
    • EditedInclusionGeneral Criteria:
    • EditedPatient or patient's legally authorized representative has understood1. All patients must agree to take part in the study and signed an IRB approvedsign a consent form for the study. Teenagers (age 13 - 17 years) and cognitively impaired adults who are able to read and write must sign an assent form (depending on local ethics committee requirements).
    • AddedPatients:
    • AddedMust have a documented, disease-causing variant(s) in a gene with a known or preliminary association with CMT gene as per Strande et al. 2017 AND consistent with the inheritance pattern associated with the genetic subtype (heterozygous in autosomal dominant, biallelic in autosomal recessive, hemizygous males with X-linked).
    • EditedPatient hasOR have a first- or second-degree family member (parent, child, sibling, half-sibling, aunt, uncle, grandparent, or grandchild) with a documented pathogenic or likely pathogenic CMTdisease-causing variant(s) as above AND a clear link between that family member and the affected patient AND a phenotype consistent with the diagnosis.
    • EditedIn cases where clear links are not available, genetic testingconfirmation is required for the patient or the family member who is not clearly affected.
    • EditedPatients who have a variant(s) of uncertain significance, as determined by the on clinical laboratory performing the testingreports may still be included if one of the following circumstances applies:
    • AddedThe variant is categorized as pathogenic or likely pathogenic per the "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology." (Richards et al., 2015)
    • AddedOR the variant has been found in multiple affected people in a family and has not been found in unaffected family members per "ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classification." (Biesecker et al. 2023)
    • EditedTheOR the principal investigator and the site investigator agree that the variant(s) is (are) most likely pathogenicdisease-causing.
    • AddedControls
    • EditedPerson doesMust not have a peripheral neuropathy, as determined by the site investigator.
    • EditedPerson hasMust have understood and signed an IRB approved consent form for the study. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).
    Exclusion criteria
    • AddedPatients:
    • EditedPatient does not wish to be a part of the studyparticipate or hasdoes not signed an informedsign a consent form.
    • AddedPatient has a different potential cause for their neuropathy AND no disease-causing variant(s).
    • EditedPatient is deemedDeemed inappropriate by the Site PI.
    Sponsor Collaborators removed: Nemours Children's Hospital
    Site contacts Changed at 10 sites. See the sites
    Show 10 sites
    • Cedars-Sinai Medical Center · Los Angeles, United StatesContact t•••@cshs.org · •••4268→Y•••@cshs.org
    • Stanford University · Palo Alto, United StatesContact c•••@standfordmed.org · •••5588→m•••@stanford.edu
    • University of Colorado Hospital · Aurora, United StatesContact b•••@ucdenver.edu · •••6386→N•••@cuanschutz.edu
    • University of Miami · Miami, United StatesContact l•••@med.miami.edu · •••2550→l•••@med.miami.edu
    • Harvard/Massachusetts General Hospital · Boston, United StatesContact n•••@mgh.harvard.edu · •••6996→l•••@mgh.harvard.edu
    • University of Michigan · Ann Arbor, United StatesContact q•••@med.umich.edu→k•••@med.umich.edu
    • University of Minnesota · Minneapolis, United StatesContact h•••@umn.edu→f•••@umn.edu
    • University of Pennsylvania · Philadelphia, United StatesContact p•••@pennmedicine.upenn.edu→d•••@pennmedicine.upenn.edu
    • University of Westmead · Sydney, AustraliaContact person changed (no phone or email listed)
    • C. Besta Neurological Institute · Milan, ItalyContact d•••@istituto-besta.it · •••3001→e•••@istituto-besta.it
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01193075
Lead sponsor
Michael Shy
Collaborators
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Johns Hopkins University, National Institute of Neurological Disorders and Stroke (NINDS), King's College Hospital NHS Trust, Stanford University, University of Pennsylvania, University of Rochester, Children's Hospital of Philadelphia, Sydney Children's Hospitals Network, Rare Diseases Clinical Research Network, Muscular Dystrophy Association, National Institutes of Health (NIH), Charcot-Marie-Tooth Association, Massachusetts General Hospital, Cedars-Sinai Medical Center, University of Miami, University of Minnesota, Connecticut Children's Medical Center, University of Colorado, Denver, National Hospital for Neurology and Neurosurgery, Dubowitz Neuromuscular Centre
Responsible party
Michael Shy (Professor, University of Iowa) — Sponsor-investigator
First posted
Sep 1, 2010
Start date
Apr 1, 2010
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Nicole M Kressin, MSN, RN
Contact
UICMTClinic@uiowa.edu
319-384-6362
Tiffany Grider, MS, CGC
Contact
UICMTClinic@uiowa.edu
319-384-6362
Michael E Shy, MD
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion